Watchlist

Watchlist
Aradigm Corporation (ARDM)
Aradigm Corporation (ARDM)
3 Things In Biotech You Should Learn Today: December 3, 2017
Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Before we get started, since the recent tax bill has moved forward in Congress, it seems a go…
Your Daily Pharma Scoop: Dynavax Beyond Heplisav-B, Novartis' Cosentyx, Shire Granted ODD
This abridged "Daily Scoop" is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. Analysis of top Seeking Alpha coverage: Dynavax Today we will focus on an article on Dynavax…
Aradigm Announces FDA Advisory Committee Meeting for Linhaliq
Meeting Scheduled for January 11, 2018 Aradigm Corporation (NASDAQ: ARDM) (the Company) today announced that a meeting of the Antimicrobial Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) has been scheduled for January 11, 2018 to review the…
Midday Gainers / Losers
Gainers: NWY +23% . ARDM +23% . IMMR +21% . HOME +18% . TLYS +17% . TITN +16% . NOG +15% . VSTM +14% . MIK +13% . MDGL +12% . More news on: New York & Company, Inc., Aradigm Corp., Immersion Corporation, Stocks on the move, Read more …
FDA Ad Com January 11 for Aradigm's Linhaliq; shares up 6%
The FDA's Antimicrobial Drugs Advisory Committee will meet on Thursday, January 11 to discuss Aradigm's ( ARDM +6% ) New Drug Application (NDA) seeking approval for Linhaliq (ciprofloxacin) for the treatment of non-cystic fibrosis bronchiectasis in patients with chronic infections due to…
Quinolones And The Adcom Of Doom: Can Aradigm Achieve The Holy Grail Of Monopoly?
Super-Quick Summary of Article In my conclusion section, I've prepared a very brief summary of the entire article for those who are short on time. Intro to Aradigm and Update Summary My friends would look at me and say, Igor, that disease (bronchiectasis) does not exist anymore! …
Aradigm to Host Key Opinion Leader Meeting and Webcast on November 9 in New York City
Aradigm Corporation (Nasdaq: ARDM) (the Company) announced today that it will host a Key Opinion Leader (KOL) Breakfast on the topic of Non-Cystic Fibrosis Bronchiectasis (NCFBE) on Thursday, November 9, 2017 from 8:00-9:30 am Eastern Time in New York, NY. The breakfast meeti…
Aradigm reports Q3 results
Aradigm (NASDAQ: ARDM ): Q3 EPS of -$0.26 Revenue of $2.73M (+5360.0% Y/Y) Press Release More news on: Aradigm Corp., Earnings news and commentary, Healthcare stocks news, ,
Aradigm Announces Third Quarter 2017 Financial Results
Aradigm Corporation (NASDAQ: ARDM) (the Company) today announced financial results for the third quarter and nine months ended September 30, 2017. The Company recorded $2.7 million in revenue in the third quarter of 2017 compared with $50,000 in revenue in the third q…
Midday Gainers / Losers
Gainers: ANAB +89% . KALV +49% . LINU +41% . HMNY +27% . MNKD +26% . SRNE +24% . PBMD +20% . ARDM +18% . SSC +15% . CLSN +15% . More news on: AnaptysBio, Kalvista Pharmaceuticals, LiNiu Technology Group, Stocks on the move, Read more …
Aradigm Regains Compliance with NASDAQ Listing Requirements
Aradigm Corporation (Nasdaq:ARDM) (Aradigm" or the Company) today announced that it received notice from The NASDAQ Capital Market (NASDAQ) indicating that the Company has regained compliance under NASDAQ Listing Rule 5550(a)(2) for continued listing o…
Aradigm Corporation (ARDM)